Vicente Valero

List of Publications by Year in descending order

246 papers	29,153 citations	3919 88 h-index	5364 164 g-index
249 all docs	249 docs citations	249 times ranked	25613 citing authors

#	Article	IF	Citations
1	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 2011, 365, 1273-1283.	13.9	2,254
2	Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4414-4422.	0.8	1,243
3	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 2008, 68, 6084-6091.	0.4	916
4	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 2009, 69, 4116-4124.	0.4	768
5	Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. Journal of Clinical Oncology, 2005, 23, 7820-7826.	0.8	640
6	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4236-4244.	0.8	621
7	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 2013, 19, 5533-5540.	3.2	597
8	Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2â€“Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology, 2002, 20, 1800-1808.	0.8	564
9	Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4282-4288.	0.8	535
10	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. Journal of Clinical Oncology, 2001, 19, 2587-2595.	0.8	531
11	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	3.8	531
12	Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors. Journal of Clinical Oncology, 2006, 24, 1037-1044.	0.8	514
13	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology, 2017, 35, 1049-1060.	0.8	478
14	Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research, 2007, 13, 228-233.	3.2	434
15	High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2â€“Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology, 2009, 27, 5700-5706.	0.8	404
16	Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. Journal of Clinical Oncology, 2005, 23, 5983-5992.	0.8	383
17	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4286-4293.	0.8	379
18	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2017, 18, 1360-1372.	5.1	377

#	Article	IF	Citations
19	Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy. Journal of Clinical Oncology, 2005, 23, 9304-9311.	0.8	366
20	Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. Journal of Clinical Oncology, 2005, 23, 41-48.	0.8	352
21	Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2006, 24, 4107-4115.	0.8	336
22	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 115-126.	5.1	333
23	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 2003, 21, 2600-2608.	0.8	322
24	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 8331-8339.	0.8	266
25	Postmastectomy Radiation Improves Local-Regional Control and Survival for Selected Patients With Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy and Mastectomy. Journal of Clinical Oncology, 2004, 22, 4691-4699.	0.8	264
26	Minority cancer patients and their providers. , 2000, 88, 1929-1938.		261
27	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. Journal of Clinical Oncology, 2007, 25, 4952-4960.	0.8	258
28	Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncology, The, 2005, 6, 229-239.	5.1	255
29	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. Journal of Clinical Oncology, 2007, 25, 2650-2655.	0.8	253
30	Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology, 2014, 32, 735-744.	0.8	237
31	Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4111-4119.	0.8	235
32	Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer. Journal of Clinical Oncology, 1999, 17, 3412-3417.	0.8	234
33	Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal of Clinical Oncology, 2012, 30, 729-734.	0.8	231
34	Cancer pain management among underserved minority outpatients. Cancer, 2002, 94, 2295-2304.	2.0	226
35	Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. Journal of Clinical Oncology, 2011, 29, 149-156.	0.8	222
36	Breast Cancer Metastasis: Challenges and Opportunities. Cancer Research, 2009, 69, 4951-4953.	0.4	202

#	Article	IF	Citations
37	Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2001, 19, 628-633.	0.8	200
38	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	2.0	194
39	Epithelialâ€“Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2012, 11, 2526-2534.	1.9	194
40	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptorâ€“Positive and â€“Negative Cancers. Journal of Clinical Oncology, 2010, 28, 4316-4323.	0.8	193
41	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research, 2011, 13, R67.	2.2	188
42	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget, 2014, 5, 9864-9876.	0.8	188
43	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research, 2010, 16, 5351-5361.	3.2	185
44	Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 272-281.	0.9	185
45	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncology, The, 2007, 8, 203-211.	5.1	175
46	Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3185-3191.	0.8	173
47	Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research, 2010, 12, R5.	2.2	169
48	Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. Journal of the National Cancer Institute, 2000, 92, 225-233.	3.0	161
49	Squamous Cell Carcinoma of the Breast. Journal of Clinical Oncology, 2005, 23, 7827-7835.	0.8	159
50	Circulating tumor cells in metastatic breast cancer. Cancer, 2008, 113, 2422-2430.	2.0	156
51	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. Cancer, 2001, 92, 2523-2528.	2.0	154
52	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 509.	3.4	154
53	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216.	0.8	152
54	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical Cancer Research, 2003, 9, 2406-15.	3.2	152

#	Article	IF	Citations
55	Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal of Clinical Oncology, 2011, 29, 3739-3746.	0.8	151
56	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. Journal of Clinical Oncology, 2020, 38, 388-394.	0.8	151
57	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surgery, 2017, 152, 665.	2.2	149
58	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	5.1	148
59	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Annals of Surgery, 2018, 267, 946-951.	2.1	147
60	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy. Annals of Surgery, 2016, 264, 344-352.	2.1	144
61	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 143-149.	2.1	142
62	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clinical Breast Cancer, 2007, 7, 34-42.	1.1	141
63	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	2.2	141
64	Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 3303-3311.	0.8	139
65	Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. Oncologist, 2001, 6, 133-146.	1.9	137
66	A Management Algorithm and Practical Oncoplastic Surgical Techniques for Repairing Partial Mastectomy Defects. Plastic and Reconstructive Surgery, 2008, 122, 1631-1647.	0.7	133
67	Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2628-2634.	0.8	128
68	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	1.9	127
69	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology Biology Physics, 2014, 89, 392-398.	0.4	126
70	Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet, The, 2000, 355, 281-283.	6.3	125
71	Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clinical Cancer Research, 2002, 8, 1073-9.	3.2	125
72	Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy. Cancer Journal (Sudbury, Mass), 2003, 9, 33-41.	1.0	122

#	Article	IF	Citations
73	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research, 2009, 15, 3654-3662.	3.2	121
74	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer, 2011, 117, 1819-1826.	2.0	121
75	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. Annals of Surgery, 2018, 267, 608-616.	2.1	117
76	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology, The, 2010, 11, 358-365.	5.1	116
77	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 351-357.	0.4	114
78	Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery, 2012, 151, 710-716.	1.0	113
79	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. Journal of Clinical Oncology, 2016, 34, 3518-3528.	0.8	113
80	The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2016, 20, 262-276.	0.9	108
81	Analysis of FcÎ³ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. Clinical Cancer Research, 2012, 18, 3478-3486.	3.2	106
82	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106
83	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Research and Treatment, 2012, 133, 1067-1075.	1.1	103
84	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncology, 2016, 2, 508.	3.4	103
85	Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature. Journal of Clinical Oncology, 2006, 24, 2113-2122.	0.8	102
86	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International Journal of Cancer, 2011, 129, 417-423.	2.3	101
87	Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer, 2003, 98, 504-507.	2.0	98
88	Risks and Benefits of Taxanes in Breast and Ovarian Cancer. Drug Safety, 2000, 23, 401-428.	1.4	97
89	Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer, 2008, 112, 1455-1461.	2.0	94
90	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research, 2014, 16, 440.	2.2	94

#	Article	IF	Citations
91	Pain Education for Underserved Minority Cancer Patients: A Randomized Controlled Trial. Journal of Clinical Oncology, 2004, 22, 4918-4925.	0.8	92
92	Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 461-468.	1.0	91
93	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	1.1	91
94	Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 2012, 12, 264-269.	1.1	87
95	Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 1999, 17, 1425-1425.	0.8	86
96	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	1.9	86
97	Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology, 2016, 23, 1515-1521.	0.7	86
98	Locally Advanced Breast Cancer. Oncologist, 1996, 1, 8-17.	1.9	85
99	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447.	1.2	84
100	High incidence of germline BRCA mutation in patients with ER lowâ€positive/PR lowâ€positive/HERâ€2 neu negative tumors. Cancer, 2015, 121, 3422-3427.	2.0	78
101	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer, 2001, 92, 1775-1782.	2.0	76
102	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
103	Outcomes of children exposed in uteroto chemotherapy for breast cancer. Breast Cancer Research, 2014, 16, 500.	2.2	75
104	Characterization of long nonâ€coding RNA transcriptome in clearâ€cell renal cell carcinoma by nextâ€generation deep sequencing. Molecular Oncology, 2015, 9, 32-43.	2.1	75
105	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€“AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	5.1	74
106	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 138-145.	0.4	70
107	Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer, 2018, 124, 36-45.	2.0	70
108	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	1.1	68

#	Article	IF	Citations
109	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	1.1	68
110	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. JAMA Oncology, 2015, 1, 1311.	3.4	65
111	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Journal of Clinical Oncology, 2016, 34, 3511-3517.	0.8	64
112	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer, 2017, 25, 3295-3304.	1.0	64
113	Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy. Annals of Surgical Oncology, 2004, 11, 854-860.	0.7	62
114	Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer, 2006, 106, 1000-1006.	2.0	59
115	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.4	58
116	Accuracy of Postâ€“Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surgery, 2020, 155, e204103.	2.2	58
117	Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2001, 19, 1716-1722.	0.8	57
118	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	3.4	56
119	Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracyclineâ€•and nonanthracyclineâ€based regimens for HER2â€positive breast cancer. Cancer, 2012, 118, 2385-2393.	2.0	54
120	Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1225-1233.	0.4	52
121	Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Review of Gastroenterology and Hepatology, 2012, 6, 481-495.	1.4	52
122	Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer. Clinical Cancer Research, 2008, 14, 7909-7916.	3.2	51
123	Primary Chemotherapy in the Treatment of Breast Cancer: The University of Texas M. D. Anderson Cancer Center Experience. Clinical Breast Cancer, 2002, 3, S63-S68.	1.1	49
124	PIK3CA-activating mutations and chemotherapy sensitivity in stage IIâ€“III breast cancer. Breast Cancer Research, 2008, 10, R27.	2.2	49
125	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1300-1309.	1.9	46
126	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing. Annals of Surgery, 2016, 263, 153-161.	2.1	45

#	Article	IF	Citations
127	Pathologic complete response in breast cancer patients receiving anthracyclineâ€•and taxaneâ€based neoadjuvant chemotherapy. Cancer, 2010, 116, 4168-4177.	2.0	44
128	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. European Journal of Cancer, 2021, 143, 134-146.	1.3	44
129	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	0.8	44
130	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. , 1998, 82, 965-969.		43
131	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Annals of Surgery, 2019, 270, 147-157.	2.1	43
132	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer, 2004, 101, 1508-1513.	2.0	40
133	USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 10-17.	1.0	39
134	Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions. JAMA Surgery, 2015, 150, 152.	2.2	39
135	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	2.2	36
136	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. , 2000, 88, 2054-2060.		35
137	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2â€positive metastatic breast cancer. Cancer, 2014, 120, 1932-1938.	2.0	35
138	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986606.	1.4	35
139	Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opinion on Pharmacotherapy, 2005, 6, 1477-1491.	0.9	34
140	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	2.0	34
141	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience, 2016, 3, 164-172.	0.9	34
142	Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. International Journal of Radiation Oncology Biology Physics, 2007, 67, 490-496.	0.4	33
143	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	1.1	33
144	Minority cancer patients and their providers. Cancer, 2000, 88, 1929-1938.	2.0	33

#	Article	IF	Citations
145	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast Journal, 2010, 16, 327-330.	0.4	32
146	Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. Journal of Clinical Oncology, 2012, 30, 930-935.	0.8	31
147	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	1.9	31
148	A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 777-783.	0.4	30
149	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research, 2007, 9, R87.	2.2	29
150	Prognostic significance of occult axillary lymph node metastases after chemotherapyâ€induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer, 2009, 115, 1605-1612.	2.0	28
151	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research, 2014, 20, 5265-5271.	3.2	28
152	Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 69.	1.8	28
153	The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. Oncology Reviews, 2017, 11, 324.	0.8	28
154	Risk factors for falls in older patients with cancer. BMJ Supportive and Palliative Care, 2018, 8, 34-37.	0.8	28
155	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investigational New Drugs, 2019, 37, 345-351.	1.2	28
156	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. Oncologist, 2020, 25, 749-757.	1.9	28
157	A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, 98, 900-907.	2.0	27
158	Automated pain intervention for underserved minority women with breast cancer. Cancer, 2015, 121, 1882-1890.	2.0	27
159	Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2015, 153, 417-423.	1.1	27
160	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	1.1	27
161	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Cancer, 2006, 106, 2327-2336.	2.0	26
162	Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research and Treatment, 2013, 137, 631-636.	1.1	26

#	Article	IF	Citations
163	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	0.6	26
164	A Novel Risk Scoring System Reliably Predicts Readmission after Pancreatectomy. Journal of the American College of Surgeons, 2015, 220, 701-713.	0.2	26
165	Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology, 2019, 5, 366.	3.4	26
166	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv250.	3.0	25
167	Primary soft tissue sarcoma of the breast. Current Treatment Options in Oncology, 2001, 2, 169-176.	1.3	24
168	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 58.	3.5	23
169	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStreamÂ® in patients with breast cancer treated with primary systemic therapy. PLoS ONE, 2020, 15, e0229903.	1.1	23
170	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. British Journal of Cancer, 2019, 120, 1105-1112.	2.9	22
171	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery, 2021, 169, 708-720.	1.0	22
172	Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer, 2000, 89, 2195-2201.	2.0	21
173	Genotype-Phenotype Correlations by Ethnicity and Mutation Location inBRCAMutation Carriers. Breast Journal, 2015, 21, 260-267.	0.4	21
174	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. , 1999, 86, 1251-1257.		20
175	Phase Iâ€“II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicinâ€“cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Research and Treatment, 2013, 141, 429-435.	1.1	20
176	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. Journal of Cancer, 2015, 6, 310-318.	1.2	20
177	Update on systemic treatment for newly diagnosed inflammatory breast cancer. Journal of Advanced Research, 2021, 29, 1-12.	4.4	20
178	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist, 2016, 21, 21-27.	1.9	19
179	Outcomes in patients with earlyâ€stage breast cancer who underwent a 21â€gene expression assay. Cancer, 2017, 123, 2422-2431.	2.0	19
180	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 2018, 22, 68-76.	0.9	19

#	Article	IF	Citations
181	Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 568-577.	0.4	19
182	Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2019, 26, 3071-3079.	0.7	19
183	Overall survival in older patients with cancer. BMJ Supportive and Palliative Care, 2020, 10, 25-35.	0.8	19
184	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 325-331.	1.1	18
185	Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35Âyears or younger. Journal of Cancer Research and Clinical Oncology, 2009, 135, 141-148.	1.2	17
186	Paclitaxel-Induced Pancreatitis: A Case Report. Journal of the National Cancer Institute, 1997, 89, 91-93.	3.0	16
187	A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma. Cancer, 2003, 97, 2716-2723.	2.0	16
188	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment, 2016, 158, 67-77.	1.1	16
189	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational New Drugs, 2018, 36, 299-306.	1.2	16
190	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372.	1.1	16
191	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment, 2019, 176, 545-556.	1.1	16
192	Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Journal of Oncology Pharmacy Practice, 2014, 20, 120-129.	0.5	14
193	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer, 2017, 8, 2004-2009.	1.2	14
194	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Supportive Care in Cancer, 2018, 26, 1561-1568.	1.0	14
195	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Research and Treatment, 1999, 54, 225-233.	1.1	13
196	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-Î². Investigational New Drugs, 2018, 36, 1103-1109.	1.2	13
197	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Research and Treatment, 2019, 176, 227-234.	1.1	13
198	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. European Journal of Radiology, 2022, 149, 110220.	1.2	13

#	Article	IF	Citations
199	Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer. Cancer Investigation, 2002, 20, 29-37.	0.6	12
200	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Research and Treatment, 2018, 169, 615-623.	1.1	12
201	Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. Clinical Breast Cancer, 2008, 8, 516-521.	1.1	11
202	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5â€fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer. Cancer, 2010, 116, 1210-1217.	2.0	11
203	Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer, 2018, 124, 2299-2305.	2.0	11
204	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. Journal of Geriatric Oncology, 2018, 9, 81-83.	0.5	11
205	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer, 2001, 91, 664-671.	2.0	10
206	Ixabepilone for the treatment of breast cancer. Annals of Medicine, 2011, 43, 477-486.	1.5	10
207	Bisphosphonates and pathologic complete response to taxaneâ€•and anthracyclineâ€based neoadjuvant chemotherapy in patients with breast cancer. Cancer, 2012, 118, 326-332.	2.0	10
208	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clinical Breast Cancer, 2018, 18, e1283-e1288.	1.1	10
209	Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Research and Treatment, 2021, 185, 1-12.	1.1	10
210	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	3.2	10
211	Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. American Journal of Surgery, 2015, 210, 636-642.e1.	0.9	9
212	Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with tripleâ€•negative breast cancer. Cancer, 2021, 127, 2880-2887.	2.0	9
213	Managing Ixabepilone Adverse Events With Dose Reduction. Clinical Breast Cancer, 2013, 13, 1-6.	1.1	8
214	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
215	Phase Iâ€“II Vinorelbine (NavelbineÂ®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation. Cancer Investigation, 2001, 19, 459-466.	0.6	7
216	Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. American Journal of Surgery, 2018, 215, 693-698.	0.9	7

#	Article	IF	Citations
217	BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Academic Radiology, 2022, 29, S35-S41.	1.3	7
218	Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. Clinical Breast Cancer, 2015, 15, 37-42.	1.1	6
219	Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. Journal of Oncology Practice, 2017, 13, 555-556.	2.5	6
220	Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast Journal, 2020, 26, 1572-1582.	0.4	6
221	Racial and Ethnic Disparities in Breast Cancer: A Collaboration Between the American College of Radiology Commissions on Women and Diversity and Breast Imaging. Journal of Breast Imaging, 2021, 3, 712-720.	0.5	6
222	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in <scp>Tripleâ€Negative</scp> Breast Cancer. Journal of Magnetic Resonance Imaging, 2022, 56, 1901-1909.	1.9	6
223	Sentinel Lymph Node Dissection Is Technically Feasible in Older Breast Cancer Patients. Clinical Breast Cancer, 2010, 10, 477-482.	1.1	5
224	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clinical Chemistry, 2020, 66, 934-945.	1.5	5
225	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862.	3.2	5
226	Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. Journal of Cancer, 2014, 5, 351-359.	1.2	4
227	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology, 2020, 130, 109170.	1.2	4
228	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers, 2022, 14, 1323.	1.7	4
229	Carboplatin for early triple-negative breast cancer?. Lancet Oncology, The, 2014, 15, 676-678.	5.1	3
230	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 93, 102-110.	0.4	3
231	Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prevention Research, 2020, 13, 795-802.	0.7	3
232	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist, 2021, 26, e230-e240.	1.9	3
233	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS ONE, 2021, 16, e0250057.	1.1	3
234	Primary chemotherapy with docetaxel for the management of breast cancer. Oncology, 2002, 16, 35-43.	0.4	3

#	Article	IF	Citations
235	Neoadjuvant Therapy of Breast Cancer. American Journal of Cancer, 2006, 5, 411-425.	0.4	2
236	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. Npj Breast Cancer, 2020, 6, 11.	2.3	2
237	Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. Npj Breast Cancer, 2021, 7, 28.	2.3	2
238	Clinical Aspect of Inflammatory Breast Cancer: Diagnosis, Criteria, Controversy. , 2012, , 11-19.		2
239	Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound in Medicine and Biology, 2022, , .	0.7	2
240	Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast Journal, 2011, 17, 462-469.	0.4	1
241	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. , 2001, 92, 2523.		1
242	Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer. Echocardiography, 2017, 34, 29-36.	0.3	0
243	Abstract PD6-07: Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. , 2021, , .		0
244	Detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing.. Journal of Clinical Oncology, 2014, 32, e15225-e15225.	0.8	0
245	An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer. Breast Journal, 2020, 26, 1022-1024.	0.4	0
246	What is the best treatment recommendation for HER2+ IBC with residual disease?â€”a narrative review. Chinese Clinical Oncology, 2021, 10, 59-59.	0.4	0